DSIP

Nueropeptide

DESCRIPTION

DSIP is a well-known neuromodulator and natural somnogenic nonapeptide with
many other physiologic functions. It is typically found in the brain and easily passes
the blood-brain barrier. It is mainly prescribed for the treatment of pain condition,
alcohol and opioid withdrawal, CRH and stress related symptoms, low testosterone
(via stimulation of LH), and even sometimes as an antioxidant and anti-oncogenic
protein.

It has been discovered and heavily studied for over 40 years, yet, the mechanism of
action is still complex and not well organized. The results of studies of DSIP and its
analogues over a period of 30 years since its discovery enable one to state with
confidence that DSIP is a unique member of the family of peptide neuromodulators. It
exhibits a pronounced stress protective action and decreases stress-induced
metabolic and functional disorders in human and animal organisms exposed to a
variety of stresses. Some of the effects of the peptide are accomplished through the
modulating action on central regulatory processes, owing to the systemic antioxidant
action, the modulating influence on the activity of GABAergic, glutamatergic, and
other neuronal systems. It also works on the expression of early response genes in
brain structures, and on the activity of biosynthetic and proteolytic processes.

PROTOCOL

Content & Potency: 1 x 3ml at 1000mcg/ml: ready-to-inject subcutaneously
Suggested dosage: DSIP has traditionally been dosed as an IV infusion, however, it can
be given subcutaneously as well. Traditional doses have been 100mcg.
Often prescribed for: Pain, to help improve sleep, and to stimulate testosterone levels
via LH release.

CLINICAL RESEARCH

In several species DSIP at low doses has been shown to promote sleep. Although its
physiological role remains to be clarified, DSIP illustrates several concepts applicable to
other brain peptides. These include the bell-shaped dose-response curve, central effects
after peripheral administration, a delayed and prolonged time course, and some
penetration of the blood-brain barrier in essentially intact form. Concepts applicable to
one neuropeptide, therefore, appear to be applicable to others. In this article Abba Kastin
and colleagues review the known effects of DSIP and argue that more work needs to be
carried out before it can be labelled functionally.

Courtesy of: https://www.transformyouaz.com